Imagion Directors Take Up Entitlement in Rights Offers
Five Appendices 3Y, “Change of Director’s Interest Notice”, have been released to announce the entitlement right offers taken up by Imagion Directors. Read the Appendices
Five Appendices 3Y, “Change of Director’s Interest Notice”, have been released to announce the entitlement right offers taken up by Imagion Directors. Read the Appendices
Imagion Biosystems has released Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations. Read Appendix 4G
Imagion Biosystems has released its Annual Report to Shareholders for the year ended 31 December 2019. Read the Annual Report.
Imagion Biosystems announces that Appendix 2A – Vesting of Performance Rights has been released to the market. Read Appendix 2A – Vesting of Performance Rights.
Imagion Biosystems has announced Appendix 2A — Application for quotation of +securities. Read Appendix 2A.
Imagion Biosystems Limited previously advised that the Renounceable Rights Issue announced on 25 March 2020 (“Offer”) has closed oversubscribed and raised $2.05 million. To accommodate
Imagion Biosystems has announced a Secondary Supplementary Prospectus. Read the Secondary Supplementary Prospectus.
Imagion Biosystems has announced a Proposed Issue of Securities. Read the Proposed Issue of Securities.
The securities of Imagion Biosystems Limited (‘IBX’) will be placed in a trading halt at the request of IBX, pending it releasing an announcement. Unless
Imagion Biosystems Limited is pleased to advise that the Renounceable Rights Issue announced on 25 March 2020 (“Offer”) has closed oversubscribed and raised $2.05 million.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
We have temporarily suspended our nanoparticle operations. Please revisit us in the future. We apologize for the inconvenience. Any questions, please email: info@imagionbio.com Dismiss